NTRK1 and cancer: Carracedo et al. [22,23] demonstrated that mTORC1 inhibition leads to Akt activation through upregulation of receptor tyrosine kinases, and the combination of mTORC1 and MAPK inhibitors enhanced the growth inhibitory effect of rapamycin in several human cancer cell lines.